| GTO ID | GTC1159 |
| Trial ID | NCT00003942 |
| Disease | T-Cell Non-Hodgkin's Lymphoma |
| Altered gene | Rev |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Rev.M10|Rev.M10/polAS |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support |
| Year | 1999 |
| Country | United States |
| Company sponsor | Systemix |
| Other ID(s) | CDR0000067135|SYSTEMIX-105|UCLA-HSPC-980303601D|NCI-G99-1549 |
| Vector information | |||
|
|||
| Cohort1: RevM10 | |||||||
|
|||||||
| Cohort2: RevM10/polAS | |||||||
|
|||||||